{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Safety+and+Efficacy+Assessments&page=2",
    "query": {
      "intervention": "Safety and Efficacy Assessments",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 1999,
    "total_pages": 200,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Safety+and+Efficacy+Assessments&page=3&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Safety+and+Efficacy+Assessments&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-03T17:04:45.393Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02530905",
      "title": "Dose-Titration and Open-label Extension Study of SRP-4045 in Advanced Stage Duchenne Muscular Dystrophy (DMD) Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Duchenne Muscular Dystrophy"
      ],
      "interventions": [
        {
          "name": "SRP-4045",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sarepta Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "7 Years",
        "maximum_age": "21 Years",
        "sex": "MALE",
        "summary": "7 Years to 21 Years · Male only"
      },
      "enrollment_count": 12,
      "start_date": "2015-10-08",
      "completion_date": "2018-10-03",
      "has_results": true,
      "last_update_posted_date": "2021-05-17",
      "last_synced_at": "2026-10-03T17:04:45.393Z",
      "location_count": 3,
      "location_summary": "Los Angeles, California • Chicago, Illinois • Baltimore, Maryland",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02530905"
    },
    {
      "nct_id": "NCT01825954",
      "title": "Prospective Evaluation of RINCE to Reduce Fibromyalgia Effects - St. Joseph Mercy Oakland",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Fibromyalgia"
      ],
      "interventions": [
        {
          "name": "RINCE",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Cerephex Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "22 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "22 Years to 65 Years"
      },
      "enrollment_count": 46,
      "start_date": "2013-03",
      "completion_date": "2014-05",
      "has_results": false,
      "last_update_posted_date": "2015-09-17",
      "last_synced_at": "2026-10-03T17:04:45.393Z",
      "location_count": 1,
      "location_summary": "Pontiac, Michigan",
      "locations": [
        {
          "city": "Pontiac",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01825954"
    },
    {
      "nct_id": "NCT00943072",
      "title": "Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Central Retinal Vein Occlusion (CRVO)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Macular Edema Secondary to Central Retinal Vein Occlusion"
      ],
      "interventions": [
        {
          "name": "VEGF Trap-Eye 2.0mg",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Sham",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Regeneron Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 189,
      "start_date": "2009-07",
      "completion_date": "2012-04",
      "has_results": true,
      "last_update_posted_date": "2013-05-27",
      "last_synced_at": "2026-10-03T17:04:45.393Z",
      "location_count": 46,
      "location_summary": "Phoenix, Arizona • Tucson, Arizona • Arcadia, California + 41 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Arcadia",
          "state": "California"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00943072"
    },
    {
      "nct_id": "NCT00366145",
      "title": "Efficacy and Safety of Adult Human Mesenchymal Stem Cells to Treat Steroid Refractory Acute Graft Versus Host Disease (GVHD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Graft Versus Host Disease"
      ],
      "interventions": [
        {
          "name": "Prochymal®",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Standard of Care for GVHD",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Mesoblast, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Months",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "6 Months to 70 Years"
      },
      "enrollment_count": 260,
      "start_date": "2006-08-17",
      "completion_date": "2009-05-28",
      "has_results": false,
      "last_update_posted_date": "2022-02-10",
      "last_synced_at": "2026-10-03T17:04:45.393Z",
      "location_count": 47,
      "location_summary": "Birmingham, Alabama • Tucson, Arizona • Duarte, California + 35 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00366145"
    },
    {
      "nct_id": "NCT02222155",
      "title": "Clinical Trial to Evaluate Safety and Efficacy of CCX168 in ANCA-Associated Vasculitis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "ANCA-associated Vasculitis"
      ],
      "interventions": [
        {
          "name": "CCX168 10 mg, twice daily, plus cyclophosphamide/rituximab plus glucocorticoids",
          "type": "DRUG"
        },
        {
          "name": "CCX168 30 mg, twice daily, cyclophosphamide/rituximab plus glucocorticoids",
          "type": "DRUG"
        },
        {
          "name": "Placebo, twice daily, plus cyclophosphamide/rituximab plus glucocorticoids",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 42,
      "start_date": "2015-02-04",
      "completion_date": "2016-07-19",
      "has_results": true,
      "last_update_posted_date": "2025-03-13",
      "last_synced_at": "2026-10-03T17:04:45.393Z",
      "location_count": 39,
      "location_summary": "Huntsville, Alabama • Phoenix, Arizona • Tucson, Arizona + 36 more",
      "locations": [
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02222155"
    },
    {
      "nct_id": "NCT03171415",
      "title": "Evaluation of Safety, Efficacy and Thermogenesis-induction of RZL-012 in Overweight and Obese Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Obesity",
        "Weight Loss",
        "Overweight and Obesity"
      ],
      "interventions": [
        {
          "name": "RZL-012",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Raziel Therapeutics Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "20 Years",
        "maximum_age": "60 Years",
        "sex": "MALE",
        "summary": "20 Years to 60 Years · Male only"
      },
      "enrollment_count": 32,
      "start_date": "2017-07-25",
      "completion_date": "2018-12-28",
      "has_results": true,
      "last_update_posted_date": "2019-08-21",
      "last_synced_at": "2026-10-03T17:04:45.393Z",
      "location_count": 1,
      "location_summary": "West Bend, Wisconsin",
      "locations": [
        {
          "city": "West Bend",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03171415"
    },
    {
      "nct_id": "NCT00141934",
      "title": "A Multicentre Trial to Determine the Efficacy of AD 452 in RA Subjects.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Rheumatoid Arthritis"
      ],
      "interventions": [
        {
          "name": "AD 452",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sosei",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 232,
      "start_date": "2005-08",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2007-04-05",
      "last_synced_at": "2026-10-03T17:04:45.393Z",
      "location_count": 10,
      "location_summary": "Clearwater, Florida • Fort Lauderdale, Florida • Ocala, Florida + 7 more",
      "locations": [
        {
          "city": "Clearwater",
          "state": "Florida"
        },
        {
          "city": "Fort Lauderdale",
          "state": "Florida"
        },
        {
          "city": "Ocala",
          "state": "Florida"
        },
        {
          "city": "Sarasota",
          "state": "Florida"
        },
        {
          "city": "St. Petersburg",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00141934"
    },
    {
      "nct_id": "NCT05503264",
      "title": "A Study to Evaluate the Efficacy, Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Satralizumab in Participants With Anti-N-methyl-D-aspartic Acid Receptor (NMDAR) or Anti-leucine-rich Glioma-inactivated 1 (LGI1) Encephalitis",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "NMDAR Autoimmune Encephalitis",
        "LGI1 Autoimmune Encephalitis"
      ],
      "interventions": [
        {
          "name": "Satralizumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 122,
      "start_date": "2022-09-27",
      "completion_date": "2028-12-14",
      "has_results": false,
      "last_update_posted_date": "2026-07-10",
      "last_synced_at": "2026-10-03T17:04:45.393Z",
      "location_count": 17,
      "location_summary": "Birmingham, Alabama • La Jolla, California • Newport Beach, California + 12 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05503264"
    },
    {
      "nct_id": "NCT06215261",
      "title": "An Evaluation of the Safety and Efficacy of Methylone for the Treatment of PTSD",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Post Traumatic Stress Disorder"
      ],
      "interventions": [
        {
          "name": "Methylone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Transcend Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 62,
      "start_date": "2024-04-04",
      "completion_date": "2025-09-23",
      "has_results": false,
      "last_update_posted_date": "2025-11-25",
      "last_synced_at": "2026-10-03T17:04:45.393Z",
      "location_count": 8,
      "location_summary": "Lauderhill, Florida • Maitland, Florida • Orlando, Florida + 5 more",
      "locations": [
        {
          "city": "Lauderhill",
          "state": "Florida"
        },
        {
          "city": "Maitland",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Rockville",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06215261"
    },
    {
      "nct_id": "NCT05755139",
      "title": "Safety and Efficacy Evaluation of SMART Camera Treatment Presets for Cutaneous Lesions Using IPL",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Vascular Lesion",
        "Pigmented Lesions"
      ],
      "interventions": [
        {
          "name": "IPL with smart diagnostic handpiece",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Lumenis Be Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "21 Years to 80 Years"
      },
      "enrollment_count": 60,
      "start_date": "2022-12-04",
      "completion_date": "2023-08-15",
      "has_results": false,
      "last_update_posted_date": "2023-12-22",
      "last_synced_at": "2026-10-03T17:04:45.393Z",
      "location_count": 2,
      "location_summary": "Austin, Texas • Houston, Texas",
      "locations": [
        {
          "city": "Austin",
          "state": "Texas"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05755139"
    }
  ]
}